Javascript was detected to be disabled. Javascript is required for some functions on this website.

The Institute for Innovation & Valuation in Health Care, InnoValHC, is an independent not-for-profit research organization. It was established by scientists with medical, health economic, and econometric backgrounds, as well as hands-on management experience, to analyse health economic and treatment strategies (see Profile). Learn more about the institute's Purpose and Projects.

News

Comparative Study on HTA in England, France and Germany

Recently published Short Communication on "Health technology assessment (HTA) in England, France and Germany: What do matched drug pairs tell us about recommendations by national HTA agencies?" in the Journal of Comparative Effectiveness Research (online available as of September 2021).

Read more …

How Much Does It Cost to Research and Develop a New Drug?

Recently published Systematic Review and Assessment in the well-known journal of PharmacoEconomics - evaluating the range and suitability of published R&D cost estimates as to the degree to which they represent the actual costs of industry (online available as of August 2021).

Read more …

Report on Orphan Medicine Incentives in Europe

The European Expert Group on Orphan Drug Incentives (OD Expert Group) published a report with a set of policy proposals that will improve the OMP (Orphan Medicinal Product) incentive framework while reflecting the different stakeholder perspectives (Copenhagen Economics, May 2021).

Read more …

Virtual ISPOR Europe 2020

A panel session on the topic "Social Cost Value Analysis: Do we need an alternative health economic evaluation paradigm?" was organized and moderated by Michael Schlander and, furthermore, current research projects (e.g. a multivariate analysis on health technology assessments (HTAs) published by NICE in England and GBA/IQWiG in Germany) were presented online at the Virtual ISPOR Europe 2020 (November 16-19, 2020).

Read more …

Virtual ESMO Congress 2020

Research projects including a comparative analysis on health technology assessment (HTA) outcomes from England, France and Germany, as well as a comprehensive literature review on the development of medical costs were presented online at the Virtual ESMO Congress 2020 (September 19-21, 2020).

Read more …